Jazz Pharmaceuticals plc Authorized Dilution
Share-issuance capacity and approved equity plans, with the disclosed share class, period, approval and expiry. Gross charter headroom is authorized minus issued shares, not a forecast. Equity plan reserves may use weighted counting rules, overlap charter capacity, and must not be added to it. Outstanding awards, future grants, and proposed approvals are distinct. * denotes calculated capacity.
| As of | Authorization / plan | Share class | Authorized / approved limit (shares) | Issued shares / outstanding awards (shares) | Remaining capacity (shares / reserve units) | Approval status | Approval date | Expiry / conditions | Basis / limitations | Source |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |